Fagron versnelt globale expansie met twee strategische overnames en verkrijgt belangrijke licentie in Noord Amerika Gereglementeerde informatie - voorkennisNazareth (België)/Rotterdam (Nederland), 19 december 2025 – 7:00 AM CET Fagron versnelt globale expansie met twee strategische overnames en verkrijgt belangrijke licentie in Noord Amerika Fagron, de toonaangevende wereldwijde speler in farmaceutische bereidingen, is verheugd om twee strategische overnames aan te kondigen. Deze overnames helpen om onze globale aanwezigheid verder te versterken en capaciteiten te diversifiëren...
Fagron accelerates global expansion with two strategic acquisitions and a key North American licensing milestone Regulated information - inside informationNazareth (Belgium)/Rotterdam (The Netherlands), 19 December 2025 – 7:00 AM CET Fagron accelerates global expansion with two strategic acquisitions and a key North American licensing milestone Fagron, the leading global player in pharmaceutical compounding, is pleased to announce two strategic acquisitions that further strengthen its global footprint and diversify its capabilities. These transactions include Amber Compounding Pharmacy, a...
The surprise call on the outlook update was only open to analysts and basically served to highlight the past 10 years of growth. Nevertheless €2.30 EPRA EPS, comes above consensus and our €2.25 estimate. Xior wants to show that after 2 years of transition and flat EPS, they will show growth again. Under COO, Kristina Olsen, Xior has also improved its internal operations and budget planning for next year had already finished. The focus is on internal efficiency gains and rental growth from realis...
Belgian Telecoms: DIGI Belgium CEO Interview: ‘We are running a marathon, not a sprint' IBA: IBA to install a Rhodotron in East China. Ontex: Another quarter, another profit warning. Theon International: Backlog visibility indeed. Xior: 2026 outlook positive but with no major surprise. Events Calendar
Today Xior celebrates its 10 year listing on the Brussels stock exchange. At the same time it issued a FY26 EPRA EPS outlook and expects EPS growth of +4% in FY26 to €2.30 vs. FY25 of €2.21. Xior is confident about the future, driven by its student housing platform and 98% occupancy. It expects rental growth from additions to its scalable operations and structural market scarcity to drive rental increases. Also efficiency gains should add to profitability gains. Xior will focus on portfolio opti...
Agfa announces additional measures to adjust the cost base of its traditional film activities to the reality in the market December 4, 2025 – 7:45 a.m. CET Regulated information Agfa announces additional measures to adjust the cost base of its traditional film activities to the reality in the market Mortsel, Belgium – December 4, 2025 – 7:45 a.m. CET Agfa today announced that it plans to implement additional measures to adjust the cost base of its traditional film activities to the accelerated global market decline. These measures are an extension to the plan that was announced in Novem...
Agfa kondigt bijkomende maatregelen aan om de kostenbasis van zijn traditionele filmactiviteiten aan te passen aan de realiteit in de markt 4 december 2025 – 7:45 uur CET Gereglementeerde informatie Agfa kondigt bijkomende maatregelen aan om de kostenbasis van zijn traditionele filmactiviteiten aan te passen aan de realiteit in de markt Mortsel, België – 4 december 2025 – 7u45 Agfa kondigde vandaag aan dat het van plan is bijkomende maatregelen te nemen om de kostenbasis van zijn traditionele filmactiviteiten aan te passen aan de versnelde achteruitgang van de wereldwijde markten. Deze...
Colruyt: Only 5 stores left to divest in France. EVS: Lower end of the range becomes the base case, on longer lead times. Fagron: Two EMEA acquisitions and California license for FSS. Kinepolis: “Wicked” achieves solid box office. OCI: Divesting Rotterdam ammonia terminal for €290m. Prosus: 1HFY26 results – on track
Fagron strengthens EMEA leadership with acquisitions in Poland and Hungary and announces key developments for its North American business Regulated information - inside informationNazareth (Belgium)/Rotterdam (The Netherlands), 24 November 2025 – 7:00 AM CET Fagron strengthens EMEA leadership with acquisitions in Poland and Hungary and announces key developments for its North American business Fagron, the global leader in pharmaceutical compounding, has reinforced its EMEA position with the acquisitions of a book of business from Amara (Poland) and Magilab (Hungary). These deals support F...
Fagron versterkt leiderschap in de EMEA-regio met overnames in Polen en Hongarije en kondigt belangrijke ontwikkelingen aan voor de Noord-Amerikaanse activiteiten Gereglementeerde informatie - voorkennisNazareth (België)/Rotterdam (Nederland), 24 November 2025 – 07.00 uur CET Fagron versterkt leiderschap in de EMEA-regio met overnames in Polen en Hongarije en kondigt belangrijke ontwikkelingen aan voor de Noord-Amerikaanse activiteiten Fagron, wereldwijd marktleider in farmaceutische bereidingen, heeft zijn positie in de EMEA-regio versterkt door de overname van een klantenportefeuille va...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.